BofA raised the firm’s price target on West Pharmaceutical (WST) to $370 from $310 and keeps a Buy rating on the shares after a “strong” Q3 report. The firm, which increased its EPS estimates by 5%-6%, cites growth drivers and normalizing market conditions heading into 2026 for its Buy rating.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on WST:
- West Pharmaceutical price target raised to $355 from $320 at UBS
- West Pharmaceutical price target raised to $345 from $305 at Deutsche Bank
- West Pharmaceutical Services Reports Strong Q3 2025 Results
- West Pharmaceutical Services’ Earnings Call: Optimistic Growth Amid Challenges
- West Pharmaceutical price target raised to $390 from $350 at Evercore ISI